ruxolitinib + capecitabine

Ruxolitinib + capecitabine is an investigational **combination therapy** comprising ruxolitinib, a selective Janus kinase 1 and 2 (JAK1/JAK2) inhibitor, and capecitabine, an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite. Ruxolitinib inhibits JAK1/JAK2, thereby blocking downstream signaling involved in hematopoiesis and immune function. Capecitabine is converted to 5-FU in vivo, interfering with DNA synthesis and inhibiting tumor cell growth. The combination has been studied in phase II and III trials for patients with advanced or metastatic pancreatic cancer (post-first-line chemotherapy) and HER2-negative breast cancer, predominately aiming to improve overall survival and progression-free survival. In these studies, the combination was generally well tolerated but did not consistently improve survival in unselected patient populations. Subgroup analyses suggested some survival benefit in pancreatic cancer patients with systemic inflammation (elevated CRP)[1][2][3][4][5][6].

Brand names

Jakafi + capecitabineJakavi + capecitabineruxolitinib + capecitabine

Other names

ruxolitinib plus capecitabine